Great Elm Capital Earnings Call Transcripts
Fiscal Year 2026
-
NAV declined due to unrealized losses, but NII rose 13% sequentially, aided by incentive fee waivers. Deleveraging actions, increased first lien exposure, and a strong liquidity position support a focus on NAV protection and sustainable income.
Fiscal Year 2025
-
Leadership transition, incentive fee waiver, and portfolio repositioning improved resilience and liquidity. Q4 NII rose over 50% sequentially, while NAV declined due to market volatility and credit headwinds. Strong liquidity and disciplined capital allocation position the company for future opportunities.
-
Q3 2025 saw a sharp NAV decline due to First Brands' bankruptcy, but strong liquidity, capital raises, and specialty finance performance position the company for a significant NII rebound in Q4. Portfolio diversification and capital redeployment remain key priorities.
-
Record investment income and NAV growth were driven by CLO platform expansion and CoreWeave gains. NII and distributions are expected to remain strong for 2025, despite some non-accruals and market volatility. Portfolio quality and capital position remain robust.
-
Record Q1 2025 investment income and NII growth were driven by CLOJV and new investments, with strong dividend coverage and a defensive, diversified portfolio. Despite modest NAV declines from unrealized losses, the outlook remains positive for NII and dividend coverage in 2025.
Fiscal Year 2024
-
Q4 2024 results reflected temporary NII and NAV declines due to CLO JV timing and equity raises, but strong multi-year growth, improved asset quality, and a 6% dividend increase position the company for robust 2025 performance. Portfolio expansion, capital raises, and strategic initiatives support a positive outlook.
-
Record investment income and strong NII growth drove a solid quarter, with stable NAV and reduced non-accruals. Specialty finance faced headwinds, but portfolio quality improved and debt maturities were extended, supporting future growth.
-
Solid Q2 performance featured over $90M in new capital, expansion into CLOs, and improved specialty finance results. NAV per share declined due to non-accruals, but NII and portfolio yield remain strong, with expectations for higher income in H2 2024.